Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Glioblastoma 21Brain Neoplasms 15Central Nervous System Neoplasms 14Astrocytoma 9Glioma 7Oligodendroglioma 5Medulloblastoma 4Neoplasms 3Lymphoma 3Gliosarcoma 3Recurrence 2Melanoma 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Uveal Melanoma 1Spinal Cord Neoplasms 1Solid Tumor 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors 1Lung Neoplasms 1Intraocular Lymphoma 1Familial ependymoma 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Cognition Disorders 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Ipilimumab 114pembrolizumab 94Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Melanoma × Lomustine × Clear all
NCT00527657 2018-11-14

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

M.D. Anderson Cancer Center

Phase 1 Completed
17 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡